Clinical trial · Observational
Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
NCT05649475CI-TRIAL-00064226unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Stage I-III Breast Cancer | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients receiving neoadjuvant therapy
Primary outcomes (2)
- measure
- Miller-Payne grading system
- timeFrame
- 3 years
- measure
- Residual cancer burden (RCB)
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is ≥ 18 years-old at the time of consent to participate this trial * Patients with stage I-III invasive breast cancer * No prior anti-cancer treatment * Felt to be a possible candidate for neoadjuvant therapy by their physician Exclusion Criteria: * Known to have other aggressive malignant tumor in the past 5 years. * Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators. * There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia. * The investigator determines that subjects are not appropriate to participate in the study due to other factors.
References
Publications (0)
Data not yet available
No reference posted for this study.